These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32304400)

  • 21. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disorders of gut-brain interaction and the long-term risks of opioids.
    Sahota S; Fortun P
    Br J Hosp Med (Lond); 2019 Oct; 80(10):C150-C154. PubMed ID: 31589497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsible prescribing of opioids for the management of chronic pain.
    Nicholson B
    Drugs; 2003; 63(1):17-32. PubMed ID: 12487620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of extended-release opioid analgesics for the treatment of chronic pain.
    Gudin JA
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):49-61. PubMed ID: 23527669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.
    Olson KM; Lei W; Keresztes A; LaVigne J; Streicher JM
    Yale J Biol Med; 2017 Mar; 90(1):97-110. PubMed ID: 28356897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioids for pain.
    Med Lett Drugs Ther; 2018 Apr; 60(1544):57-64. PubMed ID: 29664446
    [No Abstract]   [Full Text] [Related]  

  • 27. Lymphocyte opioid receptors as innovative biomarkers of osteoarthritic pain, for the assessment and risk management of opioid tailored therapy, before hip surgery, to prevent chronic pain and opioid tolerance/addiction development: OpMarkArt (Opioids-Markers-Arthroprosthesis) study protocol for a randomized controlled trial.
    Malafoglia V; Celi M; Muscoli C; Ilari S; Lauro F; Giancotti LA; Morabito C; Feola M; Tarantino U; Raffaeli W
    Trials; 2017 Dec; 18(1):605. PubMed ID: 29258584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioids for the treatment of arthritis pain.
    Stein C; Baerwald C
    Expert Opin Pharmacother; 2014 Feb; 15(2):193-202. PubMed ID: 24283649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
    Cohen JP; Mendoza M; Roland C
    Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Something for pain: Responsible opioid use in emergency medicine.
    Strayer RJ; Motov SM; Nelson LS
    Am J Emerg Med; 2017 Feb; 35(2):337-341. PubMed ID: 27802876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in opioid prescription for chronic non-cancer pain.
    Snidvongs S; Mehta V
    Postgrad Med J; 2012 Feb; 88(1036):66-72. PubMed ID: 21725034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. General pharmacology of long-acting, extended-release, and sustained-release opioids for the treatment of chronic nonmalignant pain.
    Davis MP; Gamier P; Sloan PA
    J Opioid Manag; 2015; Suppl():11-20. PubMed ID: 25539289
    [No Abstract]   [Full Text] [Related]  

  • 35. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpreting labels of abuse-deterrent opioid analgesics.
    Webster LR
    J Opioid Manag; 2017; 13(6):415-423. PubMed ID: 29308588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
    Vadivelu N; Schermer E; Kodumudi G; Berger JM
    CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.